AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL
New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.
NOTRELOAD AI
Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.
FDA Clears Gain Therapeutics’ GT-02287 for Phase 2 Parkinson’s Trials
Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.
AeroVironment Soars on Record Q4 Results, Beats Expectations by Wide Margin
AeroVironment reported record Q4 FY2026 revenue of $641.6M (+133% YoY) and non-GAAP EPS of $1.84, beating expectations.
Jana Partners Raises Stake in Alkami to Over 10% and Intensifies Sale Push
The activist investor is pushing for leadership changes and a broad sale process.
Edwards’ Ecliptis Wins FDA Clearance, Challenges AtriCure in Surgical LAA Market
Edwards got FDA OK for heart clip; it enters a market led by AtriCure, adding competition but not changing the outlook much.